LIXTE Biotechnology And The Spanish Sarcoma Group Enroll First Patient In A Phase 1b/2 Randomized Trial Of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, In Advanced Soft Tissue Sarcomas
Portfolio Pulse from Benzinga Newsdesk
LIXTE Biotechnology and the Spanish Sarcoma Group have enrolled the first patient in a Phase 1b/2 randomized trial of doxorubicin +/- LIXTE's lead anti-cancer compound, LB-100, in advanced soft tissue sarcomas.
June 07, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LIXTE Biotechnology has enrolled the first patient in a Phase 1b/2 trial of its lead anti-cancer compound, LB-100, which could potentially lead to positive results and increased investor interest.
The enrollment of the first patient in the Phase 1b/2 trial is a significant milestone for LIXTE Biotechnology. Positive results from the trial could lead to increased investor interest and a potential rise in the stock price. However, it is important to note that the trial is still in its early stages, and the outcome is uncertain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100